Abstract BACKGROUND Farming populations may face a disproportionate share of adverse exposures influencing Alzheimer's disease (AD), yet farming data are rarely connected to cohorts with characterized AD neuropathology. Whether early‐life exposure is related to AD neuropathology is limited. METHOD Brain donors from two...
W. Powell, Eleanna M. Melcher, Rachel C. Otte et al.· Alzheimer's & Dementia· 0 citations
Abstract Objectives This article summarizes the architecture, design principles, and implementation strategy of the ATRI Laboratory Information Management System (LIMS), a cloud‑native, open‑source platform supporting biomarker‑driven Alzheimer’s disease (AD) clinical research. The system addresses challenges associate...
G. Jimenez-Maggiora, S. Bruschi, S. Abdel-Latif et al.· JAMIA Open· 0 citations
Cardiovascular risk factors are implicated in Alzheimer disease (AD) progression and its neuropathological hallmarks but their specific contributions to regional brain pathology within AD remain understudied. In this cohort study (n = 276), we examined associations between diabetes, hypertension, and hypercholesterolem...
David Garcia, Hsin-Pei Wang, Naomi Saito et al.· Journal of Neuropathology an...· 0 citations
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with few treatment options, especially for APOE4/4 homozygotes who carry high genetic risk. Valiltramiprosate/ALZ-801 is an oral small-molecule inhibitor of amyloid-beta oligomer formation in late-stage development as a disease-modifying therapy for A...
J. Hey, S. Abushakra, A. Power et al.· Drugs· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.